 The European Commission EC has approved BioMarin Pharmaceutical Incs NASDAQ: BMRN Voxzogo vosoritide once-daily injection to treat achondroplasia. The approval covers children from 2 years until growth plates are closed, which occurs after puberty when children reach final adult height. 